Limited Submission Funding Opportunities – *updated 8/20/21*

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. *Name of the Principal Investigator with appropriate contact information*
2. *A descriptive title of the potential application*
3. *Brief description of the project*
4. *Brief description of why you specifically should be selected to receive institutional nomination for this award*

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-010.html
MGH LOI Deadline: 8/24/21
NIH LOI Deadline: 9/20/21
NIH Application Deadline: 10/20/21

This Funding Opportunity Announcement (FOA) invites a single cooperative agreement application for a data coordinating center that first establishes a biorepository of human cardiovascular (CV) tissue and then serves as a coordinating center resource for discovery and mechanistic research to increase our knowledge of the CV complications of type 1 diabetes (T1D). Cardiovascular disease (CVD) is the leading cause of death and morbidity for individuals with T1D, but no T1D-specific therapy exists to prevent or

treat this complication of diabetes because of challenges from inadequate preclinical models, decades-long disease progression and poorly defined differences in pathogenesis compared to type 2 diabetes (T2D). The FOA will support a two-phase research plan to encourage the use of human CV tissue to overcome these challenges. The goal of the first phase is to establish a biorepository through 1) the collection and storage of human cadaveric tissues from donors with T1D, T2D, and without diabetes; 2) the performance of quality control and basic histopathologic examination; and 3) the creation of a process for distribution of the biosamples and data to qualified investigators. The goal of the second phase is to serve as a coordinating center resource for investigators seeking to perform a multimodal analysis to deeply phenotype the anatomical, cellular, and molecular composition of the tissues and make the results available in a public data portal.

2. Parker B. Francis Fellowship in Pulmonary Research – NEW!

https://www.francisfellowships.org/apply-for-the-fellowship/

MGH LOI Deadline: 8/30/21

Sponsor Application Deadline: 10/11/21

The Parker B. Francis Fellowship provides research support to clinical and basic scientists embarking on careers in clinical, laboratory or translational science related to Pulmonary, Critical Care and Sleep Medicine. The ideal candidate is one with evidence of strong aptitude in research and who is in transition from post-doctoral trainee to independent investigator. It is essential that there be evidence of accomplishment and proficiency in research. Few applicants who are just beginning research training and have only one or two research publications are funded.

A broad array of approaches to pulmonary and critical care medicine, ranging from cell and molecular studies, to those involving epidemiologic and clinical aspects of human subjects are appropriate. We also encourage applications from pulmonary medicine specialists interested in pursuing research in bioethical aspects of pulmonary medicine or critical care. Potential topics include, but are not limited to, the ethics of clinical trials in critical care, end-of-life decisions and resource allocation. The context of all these topics should be pulmonary biology and lung disease.

Applicants are eligible to apply for a PBF Fellowship if at the time of application they are:

1. Scientists holding a relevant doctoral degree (e.g., M.D., Ph.D., Sc.D., D.V.M., Dr. P.H.) who are embarking on a career in clinical, laboratory or translational science related to Pulmonary, Critical Care and Sleep Medicine at a U.S. or Canadian university or research institution.

2. A citizen or permanent resident of the U.S. or Canada or have a permanent residency application on file at the time of application with the U.S. or Canadian Immigration Services.

3. A Ph.D. or other non-M.D. scientist no more than seven years beyond completion of their doctoral degree or an M.D. scientist no more than seven years beyond clinical training (i.e., residency, internship, clinical fellowship) at the time of application. Candidates with greater than seven years since the doctoral degree require approval for continued training from the Scientific Director of the PBF Fellowship Program.

Each department may submit a maximum of two applications.

3. Genome Research Experiences to Attract Talented Undergraduates into the Genomics Field to Enhance Diversity (R25 Clinical Trial Not Allowed)

https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-033.html

MGH LOI Deadline: 10/01/21

NIH LOI Deadline: 11/01/21

NIH Application Deadline: 12/01/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- Research Experiences
- Courses for Skills Development

This Genome Research Experiences to Attract Talented Undergraduates into the Genomic Field to Promote Diversity (GREAT) Program will support collaborative institutional partnerships that provide research education programs for undergraduates enrolled at minority-serving institutions (MSIs) or Institutional Development Award (IDeA)-eligible institutions. A partnership will include a MSI or IDeA-eligible institution, and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in scientific areas of interest to NHGRI.